Blaine Carnie

Mr. Blaine Carnie

Fiona Elsey Cancer Research Institute, Ballarat, Victoria, Australia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2026 in Cells
Verified
Journal Article
Open access
PDF file
Farah Ahmady-NieldFarah Ahmady-Nield
Farah Ahmady-Nield
BCBlaine Carnie
Blaine Carnie
GAGrace Elizabeth Constable Anderson
Grace Elizabeth Constable Anderson
EAEmerson Achari
Emerson Achari
Amit SharmaAmit Sharma
Amit Sharma
Rodney B. LuworRodney B. Luwor
Rodney B. Luwor
Glioblastoma is the most aggressive form of brain tumor resulting in low overall patient survival rates of 12–15 months post diagnosis. Several factors contribute to the complexity of the tumor, including tumor heterogeneity, blood–brain barrier complications, genetic defects, cancer stem cell generation, and immune evasion. These factors can result in the progression of glioblastoma and are controlled by signaling pathways. Some of the signaling pathways involved in glioblastoma progression include ERK, NF-κB, Wnt, and PI3K/AKT/mTOR. Our and others’ previous studies have found that TIM-3 and TGF-β signaling is altered in glioblastoma patients and may contribute to cancer progression. Immune promoting pathways such as STING have also been studied in glioblastoma to enhance anti-tumor immunity; however the interconnecting roles of these pathways are not well described. This review highlights the role of these three key cancer-related pathways in glioblastoma and their mechanistic link. Better understanding these links may result in improved treatment targets or disease progression biomarkers.

Verified
Journal Article
Open access
PDF file
PCPeter Paramaseeven Curpen
Peter Paramaseeven Curpen
Farah Ahmady-NieldFarah Ahmady-Nield
Farah Ahmady-Nield
BCBlaine Carnie
Blaine Carnie
GAGrace E. C. Anderson
Grace E. C. Anderson
George KannourakisGeorge Kannourakis
George Kannourakis
Rodney B. LuworRodney B. Luwor
Rodney B. Luwor
Glioblastoma is the most aggressive primary brain malignancy, characterised by extensive intra-tumoural heterogeneity, therapy resistance, and a profoundly immunosuppressive tumour microenvironment. The galectin family, a group of β-galactoside-binding lectins, has emerged as a key regulator of tumour biology, influencing oncogenesis, immune modulation, and therapy resistance. In this study, we performed an integrative bioinformatics analysis to systematically evaluate the expression patterns, prognostic significance, genetic alterations, and functional roles of galectin family members in glioblastoma. We utilised publicly available genomic datasets and computational tools to perform our analysis, including UALCAN, GEPIA, cBioPortal, STRING, GeneMANIA, DAVID, and TIMER. We identified LGALS1, LGALS3, and LGALS9 as significantly upregulated in glioblastoma, with their overexpression correlating with adverse patient survival. Functional enrichment analysis highlighted galectin-mediated pathways involved in extracellular matrix remodelling, immune dysregulation, tumour-promoting pathways, and protein processing, suggesting their pivotal role in glioblastoma pathogenesis. We also show that transcriptional and immunological signatures suggest that galectins may regulate glioblastoma immunosuppression, extracellular matrix remodelling, and protein homeostasis. Our findings provide novel insights into the oncogenic and immunoregulatory roles of galectins in glioblastoma, establishing their potential as prognostic biomarkers and therapeutic targets.